Sign In
Buy TARA
$3.92
-0.110 (-2.73%)
At Close: Jul 31, 2026
Protara Therapeutics: Carving New Roads In Bladder Cancer
05:00pm, Tuesday, 10'th Dec 2024
Protara Therapeutics' TARA-002 shows promising early data in bladder cancer, with a 72% complete response rate at 6 months in a small phase 2 trial. Financially, TARA has 7-8 quarters of funds, potent
Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst
03:55pm, Tuesday, 10'th Dec 2024
Initial data from the phase 2 ADVANCED-2 study, using TARA-002 for the treatment of patients with non-muscle invasive bladder cancer, is expected by mid-2025. The global bladder cancer market size is
Protara Announces Pricing of $100 Million Public Offering
11:35pm, Monday, 09'th Dec 2024
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare
Protara Announces Proposed Public Offering
04:01pm, Monday, 09'th Dec 2024
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare
TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy
10:35am, Friday, 06'th Dec 2024
Protara stock surges 70% as investigational cell therapy, TARA-002, shows superior six-month efficacy in phase II bladder cancer study.
Why Is Protara Therapeutics Stock Skyrocketing Over 100% On Thursday?
10:50am, Thursday, 05'th Dec 2024
On Thursday, Protara Therapeutics Inc. TARA stock traded higher after the company revealed results from its ongoing Phase 2 open-label ADVANCED-2 trial.
NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, toda
Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
08:00am, Wednesday, 06'th Nov 2024
NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, toda
NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today
NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, toda
NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, toda
Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08:00am, Tuesday, 03'rd Sep 2024
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, tod
Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:06pm, Monday, 24'th Jun 2024
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases, today
Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit
08:00am, Tuesday, 21'st May 2024
NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today
Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update
08:00am, Thursday, 02'nd May 2024
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today
